Semaglutide, sold under the brand name Wegovy, has already been approved for weight management in people with obesity.
Now, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug for a new purpose – to help reduce the risk of heart problems in people who are overweight or obese.
It is the first weight-loss drug approved in the UK as a preventative treatment for those with “established cardiovascular disease”, the MHRA said.
By Ella Pickover.
Full story at Yahoo News.
No comments:
Post a Comment